Prelude Therapeutics (PRLD) Revenue (2024 - 2026)

Prelude Therapeutics has disclosed Revenue across 3 years of filings, most recently posting $4.6 million for Q1 2026.

• Revenue for Q1 2026 came in at $4.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $16.7 million (changed N/A YoY), and the FY2025 annual result was $12.1 million, up 73.43% from the prior year.
• Revenue came in at $4.6 million for Q1 2026 at Prelude Therapeutics, down from $5.6 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $6.5 million in Q3 2025 to a low of $3.0 million in Q3 2024.
• The 3-year median for Revenue is $4.6 million (2026), against an average of $4.7 million.
• Peak annual rise in Revenue reached 116.67% in 2025, while the deepest fall reached 41.0% in 2025.
• Prelude Therapeutics' Revenue stood at $4.0 million in 2024, then surged by 41.0% to $5.6 million in 2025, then slipped by 18.79% to $4.6 million in 2026.
• The last three Revenue figures came in at $4.6 million (Q1 2026), $5.6 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.